Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours

Bibliographic Details
Main Author: Clemente, Gonçalo dos Santos
Publication Date: 2011
Other Authors: Duarte, Vera Lúcia Serra
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10316/109988
https://doi.org/10.1590/S1984-82502011000100010
Summary: Erythropoietin (EPO) is a glycoprotein hormone responsible for regulating erythropoiesis. Expression of EPO and EPO receptors (EPOr) has recently been demonstrated in some neoplastic cell lines and tumours, suggesting a potential new target for therapy. In this work, EPO was labeled with iodine-125 using the lactoperoxidase method, known to prevent damage to protein during radioiodination, and labeling conditions were optimized. In vitro stability studies have shown that 125I-EPO is radiochemically stable for 20 days after radiolabeling. In vitro cell binding studies have demonstrated very low binding (<2%) of EPO to normal and neoplastic cell lines tested. As expected, the biodistribution in healthy mice exhibited comparatively high rates of fixation in the organs of the excretory system. Thyroid also proved to be a critical organ which may indicate in vivo dissociation of 125I-EPO. In mice with induced melanoma, only a residual fixation in the tumour was evident. Further studies are warranted on other tumoral cell lines to better understand the binding process and internalization into cells. Studies on EPO labeled with carbon-11 could be valuable, since there is a greater chance of preserving the biological activity of the protein using this method.
id RCAP_534e0ce381015ea84892856b50edfbdf
oai_identifier_str oai:estudogeral.uc.pt:10316/109988
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumoursErythropoietin (EPO)Glycoprotein hormone125I-erythropoietin/synthesis125I-erythropoietin/ biological evaluationErythropoiesis/regulationRadiopharmaceuticalsIodine-125/labelledEPO expressive tumoursEritropoetinaHormônio glicoprotéico125I-erythropoietin/síntese125I-erythropoietin/ avaliação biológicaEritropoese/regulaçãoIodo-125/marcadorTumores expressores de EPOErythropoietin (EPO) is a glycoprotein hormone responsible for regulating erythropoiesis. Expression of EPO and EPO receptors (EPOr) has recently been demonstrated in some neoplastic cell lines and tumours, suggesting a potential new target for therapy. In this work, EPO was labeled with iodine-125 using the lactoperoxidase method, known to prevent damage to protein during radioiodination, and labeling conditions were optimized. In vitro stability studies have shown that 125I-EPO is radiochemically stable for 20 days after radiolabeling. In vitro cell binding studies have demonstrated very low binding (<2%) of EPO to normal and neoplastic cell lines tested. As expected, the biodistribution in healthy mice exhibited comparatively high rates of fixation in the organs of the excretory system. Thyroid also proved to be a critical organ which may indicate in vivo dissociation of 125I-EPO. In mice with induced melanoma, only a residual fixation in the tumour was evident. Further studies are warranted on other tumoral cell lines to better understand the binding process and internalization into cells. Studies on EPO labeled with carbon-11 could be valuable, since there is a greater chance of preserving the biological activity of the protein using this method.A eritropoetina (EPO) é um hormônio glicoprotéico responsável pela regulação da eritropoese. Recentemente foi demonstrado que os receptores de EPO (EPOr) estão expressos em algumas linhas celulares neoplásicas, o que sugere a sua potencialidade como um novo alvo terapêutico. Neste trabalho a EPO foi radiomarcada com iodo-125 através do método da lactoperoxidase, menos agressivo para a viabilidade biológica das proteínas. A 125I-EPO revelou ser radioquimicamente estável durante 20 dias após a síntese. Um estudo biológico in vitro em linhas celulares tumorais demonstrou que a 125I-EPO apresenta uma ligação muito fraca (<2%), tanto em células normais como nas linhagens tumorais testadas. A biodistribuição em camundongos saudáveis apresentou taxas de fixação relativamente maiores nos órgãos excretores e a tireóide revelou ser o órgão crítico, o que pode indicar a dissociação in vivo da 125I-EPO. No estudo em camundongos com melanoma induzido a fixação no tumor foi residual. Serão, no entanto, necessários novos estudos em outras linhagens tumorais para entender o seu processo de internalização e ligação nas células. Estudos da EPO radiomarcada com carbono-11 poderão também revelar-se interessantes, já que neste método há maior probabilidade da atividade biológica ser preservada.2011info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/109988http://hdl.handle.net/10316/109988https://doi.org/10.1590/S1984-82502011000100010engClemente, Gonçalo dos SantosDuarte, Vera Lúcia Serrainfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2023-11-10T10:57:11Zoai:estudogeral.uc.pt:10316/109988Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T06:01:39.415844Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
title Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
spellingShingle Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
Clemente, Gonçalo dos Santos
Erythropoietin (EPO)
Glycoprotein hormone
125I-erythropoietin/synthesis
125I-erythropoietin/ biological evaluation
Erythropoiesis/regulation
Radiopharmaceuticals
Iodine-125/labelled
EPO expressive tumours
Eritropoetina
Hormônio glicoprotéico
125I-erythropoietin/síntese
125I-erythropoietin/ avaliação biológica
Eritropoese/regulação
Iodo-125/marcador
Tumores expressores de EPO
title_short Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
title_full Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
title_fullStr Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
title_full_unstemmed Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
title_sort Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours
author Clemente, Gonçalo dos Santos
author_facet Clemente, Gonçalo dos Santos
Duarte, Vera Lúcia Serra
author_role author
author2 Duarte, Vera Lúcia Serra
author2_role author
dc.contributor.author.fl_str_mv Clemente, Gonçalo dos Santos
Duarte, Vera Lúcia Serra
dc.subject.por.fl_str_mv Erythropoietin (EPO)
Glycoprotein hormone
125I-erythropoietin/synthesis
125I-erythropoietin/ biological evaluation
Erythropoiesis/regulation
Radiopharmaceuticals
Iodine-125/labelled
EPO expressive tumours
Eritropoetina
Hormônio glicoprotéico
125I-erythropoietin/síntese
125I-erythropoietin/ avaliação biológica
Eritropoese/regulação
Iodo-125/marcador
Tumores expressores de EPO
topic Erythropoietin (EPO)
Glycoprotein hormone
125I-erythropoietin/synthesis
125I-erythropoietin/ biological evaluation
Erythropoiesis/regulation
Radiopharmaceuticals
Iodine-125/labelled
EPO expressive tumours
Eritropoetina
Hormônio glicoprotéico
125I-erythropoietin/síntese
125I-erythropoietin/ avaliação biológica
Eritropoese/regulação
Iodo-125/marcador
Tumores expressores de EPO
description Erythropoietin (EPO) is a glycoprotein hormone responsible for regulating erythropoiesis. Expression of EPO and EPO receptors (EPOr) has recently been demonstrated in some neoplastic cell lines and tumours, suggesting a potential new target for therapy. In this work, EPO was labeled with iodine-125 using the lactoperoxidase method, known to prevent damage to protein during radioiodination, and labeling conditions were optimized. In vitro stability studies have shown that 125I-EPO is radiochemically stable for 20 days after radiolabeling. In vitro cell binding studies have demonstrated very low binding (<2%) of EPO to normal and neoplastic cell lines tested. As expected, the biodistribution in healthy mice exhibited comparatively high rates of fixation in the organs of the excretory system. Thyroid also proved to be a critical organ which may indicate in vivo dissociation of 125I-EPO. In mice with induced melanoma, only a residual fixation in the tumour was evident. Further studies are warranted on other tumoral cell lines to better understand the binding process and internalization into cells. Studies on EPO labeled with carbon-11 could be valuable, since there is a greater chance of preserving the biological activity of the protein using this method.
publishDate 2011
dc.date.none.fl_str_mv 2011
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/109988
http://hdl.handle.net/10316/109988
https://doi.org/10.1590/S1984-82502011000100010
url http://hdl.handle.net/10316/109988
https://doi.org/10.1590/S1984-82502011000100010
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833602552722096128